This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 1999;281:1261.

	Since this article does not have an abstract, we have provided the first 137 words of the full text and any section headings.

Bethesda, Md—The Vaccines and Related Biological Products Advisory Committee to the US Food and Drug Administration has made a final decision on the three antigenic constituents of next year's influenza vaccine.

It unanimously recommended, in the absence of any compelling reason for change, retaining in the vaccine for use this fall the H3N2 component represented by A/Sydney/05/97. Earlier, the committee had recommended retaining in the vaccine the H1N1 component of influenza A, known as A/Beijing/262/95 (JAMA. 1999;281:887-888).

There was a delay in choosing the third component while the antigenicity and growth characteristics of various candidate B viruses were assessed. It's now been decided that the B component will be B/Yamanashi/166/98, said Roland Levandowski, MD, supervising medical officer in the Division of Viral Products of the FDA's Center for Biologics Evaluation and Research.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?